Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| PCS-1504-30370 | Other Identifier | PCORI |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Patient-Centered Outcomes Research Institute | OTHER |
| University of California, San Francisco | OTHER |
| Dartmouth College | OTHER |
| Kaiser Permanente |
Not provided
Not provided
Not provided
Not provided
This Breast Cancer Surveillance Consortium (BCSC) ADVANCE study is a large, observational pragmatic comparative effectiveness research study using high-quality, prospectively collected data from BCSC registries to generate evidence on how breast density should be integrated into decision making around breast cancer screening and preoperative diagnostic work-up. We will augment existing BCSC registry infrastructure with additional prospective data collection and collection of patient reported outcomes (PROs), CISNET modeling of long-term screening outcomes, and qualitative data from focus groups with women represented in two aims.
Aim 1: Compare the effectiveness of breast cancer screening using digital mammography alone versus digital mammography plus supplemental screening (digital breast tomosynthesis or MRI) by extent of breast density.
Sub aim 1: Evaluate whether the performance of tomosynthesis improves with years of experience, and whether any "learning curve" depends on radiologist specialty (i.e., breast imaging specialist vs. general radiologist).
Aim 2: Compare the effectiveness of preoperative MRI versus no MRI by extent of breast density among women with an initial, pathologically confirmed diagnosis of DCIS or invasive breast cancer.
Covid-19 Enhancement Aim and Hypotheses:
Develop patient-focused messaging content through focus groups that radiology facilities can use when scheduling appointments to inform women of the safety to schedule or postpone breast screening or diagnostic services.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Screening group | Women without a history of breast cancer undergoing screening digital mammography, screening digital breast tomosynthesis, or screening breast magnetic resonance imaging. |
| |
| Women with breast cancer | Women diagnosed with stage 0-III breast cancer undergoing pre-operative work-up with diagnostic mammography alone or diagnostic mammography plus pre-operative breast magnetic resonance imaging. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Screening digital mammography | Other | Screening with digital mammography alone |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Screening Benefits: Rate of early stage invasive cancer detection (Aim 1) | Number of stage I or IIA cancers diagnosed within 1 year of a positive screen divided by total number of screens | Within one year after screen |
| Screening Failures: Interval or advanced breast cancer rate (Aim 1) | Number of invasive cancer cases within 1 year of a negative screen divided by total number of screens Number of advanced cancers (stage IIB or higher) within 1 year of a screen divided by total number of screens | Within one year after screen |
| Screening Harms: Recall rate (Aim 1) | Number of positive screens divided by total number of screens | Within one year after screen |
| Screening Harms: False-positive (FP) recall rate (Aim 1) | Number of positive screens without a cancer diagnosed within 1 year divided by total number of screens | Within one year after screen |
| Screening Harms: FP biopsy recommendation rate (Aim 1) | Number of screens with a biopsy recommendation and no cancer diagnosed within 1 year divided by total number of screens | Within one year after screen |
| Screening Harms: Other consequences (Aim 1) | Number of DCIS diagnoses within 1 year of a positive screen divided by total number of screens, reported overall and by grade | Within one year after screen |
| Patient Reported Outcomes (Aim 1) |
| Measure | Description | Time Frame |
|---|---|---|
| Performance Measures: Sensitivity (Aim 1) | Number of cancer cases within 1 year of positive screen divided by number of breast cancer cases | Within one year after screen |
| Performance Measures: Specificity (Aim 1) |
| Measure | Description | Time Frame |
|---|---|---|
| Modeled Long-Term Mortality Outcome: Breast cancers deaths averted (Aim 1) | Breast cancers deaths averted estimated by the Cancer Intervention and Surveillance Modeling Network (CISNET) models | From date of first screening examination until the date of death from any cause, up to 100 years of age |
| Modeled Long-Term Mortality Outcome: Life-years gained (Aim 1) |
Aim 1 Clinical Outcomes
Inclusion criteria:
Exclusion criteria:
Aim 1 Patient Reported Outcomes
Inclusion criteria:
Aim 1 Focus Groups
Inclusion criteria:
Subaim 1
Inclusion criteria:
Exclusion criteria:
Aim 2 Clinical Outcomes
Inclusion criteria:
Aim 2 Patient Reported Outcomes
Inclusion criteria:
Aim 2 Focus Groups
Inclusion criteria:
COVID-19 Enhancement Focus Groups
Inclusion criteria:
Women age 18-74 who were due for breast imaging services during the COVID pandemic and have either canceled their appointment, delayed their appointment, or kept their appointment
Women who are able to speak English and can attend calls virtually through Zoom or over the phone
In addition, for focus groups with women who have prior breast cancer:
Not provided
Not provided
This study will include women age 40-79 undergoing screening mammography (Aim 1) and women age ≥18 with a first breast cancer diagnosis (Aim 2). We will include women in the BCSC cohort with mammography from 2005-2017. BCSC participants are identified from seven BCSC breast imaging registries. The BCSC prospectively collects data during routine clinical practice through voluntary partnerships with radiology facilities. Women enter the BCSC cohort when they receive a breast-imaging exam at a participating facility.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Diana L Miglioretti, PhD | University of California, Davis | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sacramento Area Breast Imaging Registry | Davis | California | 95616 | United States | ||
| San Francisco Mammography Registry |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38685119 | Derived | Smith RE, Sprague BL, Henderson LM, Kerlikowske K, Miglioretti DL, Wernli KJ, Onega T, diFlorio-Alexander RM, Tosteson ANA. Breast density knowledge and willingness to delay treatment for pre-operative breast cancer imaging among women with a personal history of breast cancer. Breast Cancer Res. 2024 Apr 29;26(1):73. doi: 10.1186/s13058-024-01820-x. | |
| 36356184 |
| Label | URL |
|---|---|
| Breast Cancer Surveillance Consortium (BCSC) | View source |
Not provided
Please visit http://www.bcsc-research.org for information about requesting BCSC data.
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Feb 28, 2022 | |
| Unrelease | Feb 28, 2022 | |
| Release | Dec 22, 2022 |
Not provided
| OTHER |
| University of Vermont | OTHER |
| University of North Carolina | OTHER |
| University of Illinois at Chicago | OTHER |
| Wake Forest University Health Sciences | OTHER |
| Harvard Pilgrim Health Care | OTHER |
| Albert Einstein College of Medicine | OTHER |
| Erasmus Medical Center | OTHER |
Not provided
Not provided
Not provided
| Screening digital breast tomosynthesis |
| Other |
Screening with digital mammography plus digital breast tomosynthesis |
|
| Screening breast magnetic resonance imaging | Other | Screening with digital mammography plus breast magnetic resonance imaging |
|
| Diagnostic mammography | Other | Pre-operative diagnostic work-up with mammography alone |
|
| Pre-operative breast magnetic resonance imaging | Other | Pre-operative diagnostic work-up with mammography plus breast magnetic resonance imaging |
|
Patient surveys targeted to determining outcomes of interest to patients |
| Measured within one year post-screening |
| Rates of additional breast cancers detected (Aim 2) | Number of women with contralateral breast cancer diagnosed within 6 months of initial diagnosis over total number of women | 6 months after initial diagnosis |
| 3-year rate of 2nd breast cancer events (Aim 2) | Rate of 2nd breast cancers diagnosed within 3 years of follow-up (starting 6 months after initial diagnosis) calculated separately for ipsilateral and contralateral cancers | 3 years after initial diagnosis |
| Patient Reported Outcomes (Aim 2) | Patient surveys targeted to determining outcomes of interest to patients | Measured 6-18 months post-diagnosis |
Number of negative screens without cancer diagnosed within 1 year of screen divided by number of screens without breast cancer
| Within one year after screen |
| Performance Measures: Positive predictive value (Aim 1) | Number of cancer cases within 1 year of positive screen divided by number of positive screens | Within one year after screen |
| Definitive surgery type (Aim 2) | Rates of unilateral mastectomy, or bilateral mastectomy, lumpectomy with reconstruction, lumpectomy without reconstruction | 6 months after initial diagnosis |
| Negative predictive value of work-up with MRI (Aim 2) | Number of women with a negative pre-operative MRI and no additional cancers diagnosed within 6 months after initial diagnosis over the total number of women with a negative pre-operative MRI | 6 months after initial diagnosis |
| Negative predictive value of work-up without MRI (Aim 2) | Number of women without a pre-operative MRI with no additional cancers diagnosed within 6 months after initial diagnosis over the total number of women without a pre-operative MRI | 6 months after initial diagnosis |
| Core biopsy rates (Aim 2) | Number of core biopsies within 6 months of initial diagnosis over number of breast biopsies | 6 months after initial diagnosis |
| Surgical biopsy rate (Aim 2) | Number of surgical biopsies within 6 months of initial diagnosis over number of breast biopsies | 6 months after initial diagnosis |
| Benign biopsy rate (Aim 2) | Number of initial benign biopsies over number of breast biopsies | 6 months after initial diagnosis |
Life-years gained estimated by the Cancer Intervention and Surveillance Modeling Network (CISNET) models |
| From date of first screening examination until the date of death from any cause, up to 100 years of age |
| Modeled Long-Term Mortality Outcome: Overdiagnosis (Aim 1) | Overdiagnosis estimated by the Cancer Intervention and Surveillance Modeling Network (CISNET) models | From date of first screening examination until the date of death from any cause, up to 100 years of age |
| San Francisco |
| California |
| 94143 |
| United States |
| Metro Chicago Breast Cancer Registry | Chicago | Illinois | 60607 | United States |
| New Hampshire Mammography Network | Lebanon | New Hampshire | 03755 | United States |
| Carolina Mammography Registry | Chapel Hill | North Carolina | 27599 | United States |
| Vermont Breast Cancer Surveillance System | Burlington | Vermont | 05405 | United States |
| Kaiser Permanente Washington Breast Cancer Surveillance Registry | Seattle | Washington | 98101 | United States |
| Tosteson ANA, Schifferdecker KE, Smith RE, Wernli KJ, Zhao W, Kaplan CP, Buist DSM, Henderson LM, Sprague BL, Onega T, Budesky J, Jackson-Nefertiti G, Johnson D, Miglioretti DL, Kerlikowske K. Women's Breast Cancer Screening Confidence by Screening Modality and Breast Density: A Breast Cancer Surveillance Consortium Survey Study. J Womens Health (Larchmt). 2022 Nov;31(11):1547-1556. doi: 10.1089/jwh.2021.0649. |
| 34686934 | Derived | Onega T, Zhu W, Kerlikowske K, Miglioretti DL, Lee CI, Henderson LM, Tosteson ANA, Wernli KJ, diFlorio R, Weaver DL, Buist DSM. Preoperative MRI in breast cancer: effect of breast density on biopsy rate and yield. Breast Cancer Res Treat. 2022 Jan;191(1):177-190. doi: 10.1007/s10549-021-06418-x. Epub 2021 Oct 22. |
| Unrelease | Jan 11, 2023 |
| Release | May 9, 2023 |
| Reset | Feb 2, 2024 |
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Feb 28, 2022 | Feb 28, 2022 | |||
| Dec 22, 2022 | Jan 11, 2023 | |||
| May 9, 2023 | Feb 2, 2024 |
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided